JPMorgan Chase & Co. Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $36.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective decreased by JPMorgan Chase & Co. from $38.00 to $36.00 in a research note issued to investors on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

DAWN has been the subject of a number of other reports. Needham & Company LLC reissued a buy rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. Bank of America upgraded Day One Biopharmaceuticals from an underperform rating to a buy rating and increased their target price for the company from $11.00 to $24.00 in a report on Thursday, August 1st. HC Wainwright reaffirmed a buy rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Piper Sandler reiterated an overweight rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Finally, Wedbush reiterated an outperform rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $35.71.

Day One Biopharmaceuticals Stock Up 1.3 %

Shares of NASDAQ DAWN traded up $0.17 during midday trading on Tuesday, hitting $13.30. The stock had a trading volume of 144,339 shares, compared to its average volume of 924,541. The company has a market capitalization of $1.16 billion, a PE ratio of -5.23 and a beta of -1.51. The stock has a 50 day simple moving average of $13.96 and a 200-day simple moving average of $14.81. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analyst estimates of $0.90 million. As a group, analysts expect that Day One Biopharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Saira Ramasastry sold 10,000 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $13.19, for a total value of $131,900.00. Following the completion of the sale, the director now directly owns 40,485 shares in the company, valued at $533,997.15. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the transaction, the insider now owns 1,121,081 shares in the company, valued at $17,948,506.81. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Saira Ramasastry sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $13.19, for a total value of $131,900.00. Following the transaction, the director now owns 40,485 shares in the company, valued at approximately $533,997.15. The disclosure for this sale can be found here. Insiders sold a total of 46,068 shares of company stock valued at $710,473 over the last ninety days. 8.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. increased its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. SG Americas Securities LLC acquired a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $113,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at about $156,000. Finally, Arizona State Retirement System increased its holdings in Day One Biopharmaceuticals by 8.2% in the fourth quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock worth $195,000 after purchasing an additional 1,010 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.